nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CHRM4—nervous system—attention deficit hyperactivity disorder	0.00827	0.0735	CbGeAlD
Solifenacin—CHRM2—forebrain—attention deficit hyperactivity disorder	0.00818	0.0726	CbGeAlD
Solifenacin—CHRM4—central nervous system—attention deficit hyperactivity disorder	0.00796	0.0708	CbGeAlD
Solifenacin—CHRM1—forebrain—attention deficit hyperactivity disorder	0.00744	0.0661	CbGeAlD
Solifenacin—CHRM2—cardiovascular system—attention deficit hyperactivity disorder	0.00691	0.0614	CbGeAlD
Solifenacin—CHRM3—forebrain—attention deficit hyperactivity disorder	0.00666	0.0592	CbGeAlD
Solifenacin—CHRM5—nervous system—attention deficit hyperactivity disorder	0.00647	0.0574	CbGeAlD
Solifenacin—CHRM4—brain—attention deficit hyperactivity disorder	0.00632	0.0562	CbGeAlD
Solifenacin—CHRM1—cardiovascular system—attention deficit hyperactivity disorder	0.00629	0.0559	CbGeAlD
Solifenacin—CHRM5—central nervous system—attention deficit hyperactivity disorder	0.00623	0.0553	CbGeAlD
Solifenacin—CHRM5—brain—attention deficit hyperactivity disorder	0.00494	0.0439	CbGeAlD
Solifenacin—CHRM2—nervous system—attention deficit hyperactivity disorder	0.00444	0.0394	CbGeAlD
Solifenacin—CHRM2—central nervous system—attention deficit hyperactivity disorder	0.00427	0.038	CbGeAlD
Solifenacin—CHRM1—nervous system—attention deficit hyperactivity disorder	0.00404	0.0359	CbGeAlD
Solifenacin—CHRM1—central nervous system—attention deficit hyperactivity disorder	0.00389	0.0346	CbGeAlD
Solifenacin—CHRM3—nervous system—attention deficit hyperactivity disorder	0.00362	0.0321	CbGeAlD
Solifenacin—CHRM3—central nervous system—attention deficit hyperactivity disorder	0.00348	0.0309	CbGeAlD
Solifenacin—CHRM2—brain—attention deficit hyperactivity disorder	0.00339	0.0301	CbGeAlD
Solifenacin—CHRM1—brain—attention deficit hyperactivity disorder	0.00309	0.0274	CbGeAlD
Solifenacin—CHRM3—brain—attention deficit hyperactivity disorder	0.00276	0.0246	CbGeAlD
Solifenacin—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00199	0.0177	CbGeAlD
Solifenacin—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00191	0.017	CbGeAlD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000811	0.000914	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000808	0.000911	CbGpPWpGaD
Solifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000806	0.000909	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000806	0.000909	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.0008	0.000902	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000798	0.000899	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000793	0.000894	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000791	0.000891	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000784	0.000884	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000783	0.000882	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000781	0.000881	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000768	0.000865	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000766	0.000863	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000758	0.000854	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000755	0.000851	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000753	0.000848	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000751	0.000847	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000746	0.00084	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000745	0.00084	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000743	0.000838	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000743	0.000837	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000741	0.000835	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000736	0.000829	CbGpPWpGaD
Solifenacin—CHRM1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.000735	0.000828	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000734	0.000827	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000734	0.000827	CbGpPWpGaD
Solifenacin—CHRM3—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.000732	0.000825	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000722	0.000813	CbGpPWpGaD
Solifenacin—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000707	0.000796	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000703	0.000792	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000695	0.000783	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000692	0.00078	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000691	0.000779	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000686	0.000773	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000657	0.00074	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000655	0.000738	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00065	0.000732	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000648	0.00073	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000641	0.000723	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000623	0.000702	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000618	0.000697	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000617	0.000695	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000611	0.000688	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000606	0.000683	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000604	0.000681	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000604	0.000681	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000602	0.000678	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000598	0.000674	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000596	0.000672	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000596	0.000672	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000585	0.000659	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000583	0.000657	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000577	0.000651	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000575	0.000648	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000573	0.000646	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000573	0.000645	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000568	0.00064	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000568	0.00064	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000568	0.00064	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000566	0.000638	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000566	0.000638	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000566	0.000637	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000562	0.000633	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000561	0.000632	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000561	0.000632	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00056	0.000631	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000554	0.000625	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00055	0.00062	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000549	0.000619	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000548	0.000618	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000548	0.000618	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000544	0.000614	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000543	0.000612	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000542	0.00061	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000529	0.000596	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000527	0.000594	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000526	0.000593	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000522	0.000588	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000521	0.000588	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000506	0.00057	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000495	0.000557	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000494	0.000557	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000493	0.000556	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000492	0.000554	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00049	0.000552	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000488	0.00055	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000487	0.000548	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000485	0.000546	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000485	0.000546	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000482	0.000543	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000482	0.000543	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00048	0.000541	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000476	0.000536	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000473	0.000534	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000473	0.000533	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000471	0.000531	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000469	0.000529	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000462	0.00052	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000461	0.00052	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00046	0.000518	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000456	0.000514	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000453	0.00051	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000445	0.000502	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000444	0.0005	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000443	0.0005	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00044	0.000496	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000438	0.000493	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000432	0.000487	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000426	0.00048	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000425	0.000478	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00042	0.000473	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000419	0.000472	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000419	0.000472	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000415	0.000467	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000414	0.000466	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000403	0.000454	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000396	0.000446	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000386	0.000435	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000386	0.000434	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000385	0.000434	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000381	0.00043	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000381	0.00043	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00038	0.000428	CbGpPWpGaD
Solifenacin—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000378	0.000426	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000376	0.000424	CbGpPWpGaD
Solifenacin—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000375	0.000423	CbGpPWpGaD
Solifenacin—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000373	0.00042	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00037	0.000417	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000369	0.000416	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	0.000367	0.000414	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000367	0.000414	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000366	0.000412	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000366	0.000412	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000362	0.000408	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000341	0.000385	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00034	0.000383	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000337	0.00038	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000334	0.000377	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000333	0.000376	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000332	0.000374	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000332	0.000374	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000331	0.000373	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000331	0.000372	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000329	0.000371	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000329	0.000371	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000328	0.000369	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000326	0.000368	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000325	0.000366	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000325	0.000366	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000324	0.000365	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000324	0.000365	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000321	0.000362	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000321	0.000362	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000321	0.000361	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00032	0.000361	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00032	0.00036	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000319	0.000359	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000318	0.000358	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000317	0.000357	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000315	0.000355	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00031	0.00035	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00031	0.000349	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000309	0.000348	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000306	0.000345	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.0003	0.000338	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000299	0.000337	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000299	0.000337	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000298	0.000336	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000297	0.000335	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000296	0.000334	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000295	0.000333	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000295	0.000332	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000294	0.000331	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000292	0.000329	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000291	0.000328	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000291	0.000328	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00029	0.000327	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000288	0.000324	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000282	0.000318	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00028	0.000315	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000273	0.000308	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000273	0.000308	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000272	0.000306	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000271	0.000306	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000271	0.000305	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00027	0.000304	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000269	0.000303	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000268	0.000302	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000263	0.000296	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00026	0.000293	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000258	0.000291	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000255	0.000288	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000252	0.000284	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00025	0.000281	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000248	0.000279	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000244	0.000275	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000238	0.000268	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000228	0.000257	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000225	0.000254	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000225	0.000253	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000222	0.000251	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000218	0.000246	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000209	0.000236	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000209	0.000235	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000208	0.000234	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000207	0.000233	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000197	0.000222	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000196	0.000221	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000194	0.000219	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00019	0.000214	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00019	0.000214	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000188	0.000211	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000183	0.000206	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000183	0.000206	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000181	0.000204	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000177	0.0002	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000177	0.000199	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000175	0.000197	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000174	0.000196	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000174	0.000196	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000172	0.000194	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000172	0.000194	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000172	0.000193	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00017	0.000191	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000167	0.000188	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—COMT—attention deficit hyperactivity disorder	0.000165	0.000186	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000164	0.000185	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00016	0.000181	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00016	0.00018	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00016	0.00018	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000158	0.000178	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000155	0.000174	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000112	0.000127	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000112	0.000126	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000111	0.000125	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000107	0.00012	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000107	0.00012	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000105	0.000118	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.76e-05	0.00011	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.82e-05	9.94e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	8.53e-05	9.61e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.45e-05	9.52e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.12e-05	9.15e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—EP300—attention deficit hyperactivity disorder	7.09e-05	7.99e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	6.47e-05	7.29e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	6.42e-05	7.23e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.95e-05	6.7e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.93e-05	6.68e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.87e-05	6.62e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	2.77e-05	3.12e-05	CbGpPWpGaD
